The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.
 
Ronald C. Chen
Employment - University of Kansas Medical Center
Consulting or Advisory Role - Abbvie; Accuray; Accuray; Astellas Pharma; Bayer; Blue Earth Diagnostics; Genentech; Janssen; Medivation/Astellas; Myovant Sciences; Pfizer
Research Funding - Accuray
Travel, Accommodations, Expenses - Reflexion Medical; Telix Pharmaceuticals
 
Gina L. Mazza
No Relationships to Disclose
 
Briant Fruth
No Relationships to Disclose
 
Han Xiao
No Relationships to Disclose
 
Joel Picus
Research Funding - lava therapeutics (Inst); Merck (Inst); Novartis (Inst); Seagen (Inst)
 
Mary Ellen Taplin
No Relationships to Disclose
 
Tanya B. Dorff
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis; Janssen Oncology; Sanofi/Aventis
Research Funding - Pfizer (Inst)
 
Leonard Joseph Appleman
Consulting or Advisory Role - AADi
Research Funding - Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Seagen (Inst); Surface Oncology (Inst)
Other Relationship - Pfizer
(OPTIONAL) Uncompensated Relationships - Exelixis
 
Douglas Jay Weckstein
No Relationships to Disclose
 
Akash Patnaik
No Relationships to Disclose
 
Alan Haruo Bryce
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; Bayer; Bayer; Castle Biosciences; Horizon CME; Janssen; Janssen Oncology; Lilly; Myovant Sciences; Myovant Sciences; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Research to Practice; Research to Practice; Verity Pharmaceuticals; Verity Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology (Inst); Pfizer; Pfizer (Inst); Phosplatin Therapeutics (Inst)
 
Daniel Shevrin
No Relationships to Disclose
 
James L. Mohler
Honoraria - NCCN-Pfizer-Myovant
Patents, Royalties, Other Intellectual Property - Mohler JL, Fiandalo M, Watt D, Sviripa V. Compounds and methods to impair androgen receptor (AR) activation, impair dimerization, and/or impair AR transregulation. Provisional patent application 62/839,676, filed 04/27/2019, by Health Research Inc. & Univ (Inst); Mohler JL, Fiandalo M, Watt D, Sviripa V. Coumarin-modified androgens for the treatment of prostate. cancer. International Patent Cooperation Treaty PCT/US2020/03014, filed 05/14/2020 by Health Research Inc. and Univ. of Kentucky Research Foundation (Inst); Mohler JL, Fiandalo M, Watt D, Sviripa V. Inhibitors of androgen receptor activation and methods of making and using same. Provisional patent application 62/890,292, filed 08/22/2019, by Health Research Inc. & Univ. of Kentucky Research Foundation (Inst); Mohler JL, Fiandalo M, Watt D, Sviripa V. Spirocyclic dihydrotestosterone as ligand for proteolysis chimeras for AR degradation, imaging agents, and screening tools for the treatment of prostate cancer. U.S. Provisional patent application 62/844,062, file (Inst)
 
Daniel M. Anderson
No Relationships to Disclose
 
Arpit Rao
Employment - Ankr (I)
Leadership - Ankr
Stock and Other Ownership Interests - Ankr; AstraZeneca
Honoraria - Bayer; Bristol-Myers Squibb; Cardinal Health; Dendreon; Eisai; Lilly; Sanofi
Consulting or Advisory Role - Lilly (Inst)
Speakers' Bureau - Bristol Myers Squibb; Pfizer
Research Funding - Clovis Oncology (Inst); Lilly (Inst); Pfizer/Astellas (Inst); Seattle Genetics/Astellas (Inst)
 
Alan Tan
Stock and Other Ownership Interests - Adaptimmune; Aprea AB; Bluebird Bio; Editas Medicine; FATE Therapeutics; Fusion Pharmaceuticals; ImmunityBio; Iovance Biotherapeutics; MEI Pharma; natera; RAPT Therapeutics
Honoraria - Bristol Myers Squibb Foundation; EMD Serono; Exelixis; Gilead Sciences; Merck; Myovant Sciences; natera; Seagen
Consulting or Advisory Role - Exelixis; Foundation Medicine; Myovant Sciences
Speakers' Bureau - bristol myers squibb; EMD Serono; Exelixis; Gilead Sciences; Merck; natera
 
Charles J. Ryan
Honoraria - Bayer; Janssen Oncology
 
Scott Eggener
No Relationships to Disclose
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Ambrx; Arvinas; AstraZeneca; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clarity Pharmaceuticals; Convergent Therapeutics; Core Medica; Curium Pharma; Daiichi; Exelixis; Flare Therapeutics; Fusion Pharmaceuticals; ITM Isotope Technologies Munich; Lantheus Medical Imaging; Mashup Media; Pfizer; POINT Biopharma; Progenics; Telix Pharmaceuticals; Transtherabio; Z-Alpha
Research Funding - Astellas Pharma (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; APCCC; AstraZeneca; Memorial Sloan-Kettering Cancer Center
Other Relationship - Novartis
(OPTIONAL) Uncompensated Relationships - Amgen; Amgen; Bayer; Janssen Oncology; Novartis
 
Rahul Raj Aggarwal
Consulting or Advisory Role - Alessa Therapeutics; Amgen; AstraZeneca; Bayer; BioXcel Therapeutics; Boxer Capital; EcoR1 Capital; Exelixis; Janssen; Jubilant Pharmaceuticals; Merck; Novartis; OncLive.; PCCTC; Pfizer; Tersera
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Expert Testimony - University of Utah Health
Travel, Accommodations, Expenses - DAVA Oncology